Sökning: WFRF:(Piette J C) > (2010-2014) > EULAR recommendatio...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04036naa a2200565 4500 | |
001 | oai:prod.swepub.kib.ki.se:121633240 | |
003 | SwePub | |
008 | 240913s2010 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1216332402 URI |
024 | 7 | a https://doi.org/10.1136/ard.2010.1304762 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bertsias, GK4 aut |
245 | 1 0 | a EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs |
264 | c 2010-08-19 | |
264 | 1 | b BMJ,c 2010 |
520 | a To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations.MethodsThe authors compiled questions on prevalence and risk factors, diagnosis and monitoring, therapy and prognosis of NPSLE. A systematic literature search was performed and evidence was categorised based on sample size and study design.ResultsSystemic lupus erythematosus (SLE) patients are at increased risk of several neuropsychiatric manifestations. Common (cumulative incidence >5%) manifestations include cerebrovascular disease (CVD) and seizures; relatively uncommon (1–5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis. Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea). The diagnostic work-up of suspected NPSLE is comparable to that in patients without SLE who present with the same manifestations, and aims to exclude causes unrelated to SLE. Investigations include cerebrospinal fluid analysis (to exclude central nervous system infection), EEG (to diagnose seizure disorder), neuropsychological tests (to assess cognitive dysfunction), nerve conduction studies (for peripheral neuropathy) and MRI (T1/T2, fluid-attenuating inversion recovery, diffusion-weighted imaging, enhanced T1 sequence). Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity. Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD.ConclusionsNeuropsychiatric manifestations in SLE patients should be first evaluated and treated as in patients without SLE, and secondarily attributed to SLE and treated accordingly. | |
700 | 1 | a Ioannidis, JPA4 aut |
700 | 1 | a Aringer, M4 aut |
700 | 1 | a Bollen, E4 aut |
700 | 1 | a Bombardieri, S4 aut |
700 | 1 | a Bruce, IN4 aut |
700 | 1 | a Cervera, R4 aut |
700 | 1 | a Dalakas, M4 aut |
700 | 1 | a Doria, A4 aut |
700 | 1 | a Hanly, JG4 aut |
700 | 1 | a Huizinga, TWJ4 aut |
700 | 1 | a Isenberg, D4 aut |
700 | 1 | a Kallenberg, C4 aut |
700 | 1 | a Piette, JC4 aut |
700 | 1 | a Schneider, M4 aut |
700 | 1 | a Scolding, N4 aut |
700 | 1 | a Smolen, J4 aut |
700 | 1 | a Stara, A4 aut |
700 | 1 | a Tassiulas, I4 aut |
700 | 1 | a Tektonidou, M4 aut |
700 | 1 | a Tincani, A4 aut |
700 | 1 | a van Buchem, MA4 aut |
700 | 1 | a van Vollenhoven, Ru Karolinska Institutet4 aut |
700 | 1 | a Ward, M4 aut |
700 | 1 | a Gordon, C4 aut |
700 | 1 | a Boumpas, DT4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Annals of the rheumatic diseasesd : BMJg 69:12, s. 2074-2082q 69:12<2074-2082x 1468-2060x 0003-4967 |
856 | 4 | u https://ard.bmj.com/content/69/12/2074.full.pdf |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:121633240 |
856 | 4 8 | u https://doi.org/10.1136/ard.2010.130476 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy